Subject(s)
Chromosome Aberrations , Chromosome Disorders , Neuroblastoma/genetics , Oncogenes , Cell Division , Child , Chromosome Deletion , Chromosomes, Human, Pair 1 , Chromosomes, Human, Pair 11 , Chromosomes, Human, Pair 14 , Genes, MHC Class I , Humans , Infant , Insulin-Like Growth Factor II/genetics , Insulin-Like Growth Factor II/physiology , Neuroblastoma/pathology , Neuroblastoma/physiopathologyABSTRACT
Neuroblastoma is an embryonal tumor that typically arises in cells of the developing adrenal medulla. IGF-II mRNA is expressed at high levels in the adrenal cortex before birth but it is not detectable until after birth in the adrenal medulla. Neuroblastoma cell lines corresponding to early adrenal medullary precursors did not express IGF-II, although all three cell lines we tested were growth stimulated by IGF-II. Cell lines corresponding to more mature adrenal medullary cells expressed IGF-II, and one, SK-N-AS, grows by an IGF-II autocrine mechanism (J. Clin. Invest. 84:829-839) El-Badry, Romanus, Helman, Cooper, Rechler, and Israel. 1989. An examination of human neuroblastoma tumor tissues for IGF-II gene expression using in situ hybridization histochemistry revealed that IGF-II is expressed by tumor cells in only 5 of 21 neuroblastomas, but is detectable in cells of nonmalignant tissues including adrenal cortical cells, stromal fibroblasts, and eosinophils in all 21 tumors. These findings indicate that IGF-II may function as an autocrine growth factor for some neuroblastomas and as a paracrine growth factor for others. They suggest that the growth regulatory pathways utilized by neuroblastoma mimic those used in the precursor cell type from which individual tumors arise.
Subject(s)
Insulin-Like Growth Factor II/metabolism , Neuroblastoma/metabolism , Adrenal Glands/metabolism , Cell Division , Gene Expression , Humans , Immunohistochemistry , Insulin-Like Growth Factor II/genetics , Neuroblastoma/pathology , Nucleic Acid Hybridization , RNA, Messenger/analysis , Tumor Cells, Cultured/metabolism , Tumor Cells, Cultured/pathologySubject(s)
Insulin-Like Growth Factor II/genetics , Neuroblastoma/genetics , Adrenal Glands/embryology , Adrenal Glands/physiology , Cell Division/drug effects , Cell Line , Gene Expression , Humans , Insulin-Like Growth Factor II/pharmacology , Insulin-Like Growth Factor II/physiology , Neuroblastoma/pathologySubject(s)
Growth Substances/isolation & purification , Insulin-Like Growth Factor II/isolation & purification , Cell Aggregation/drug effects , Cell Division/drug effects , Cell Line , Chromatography, Gel , Culture Media , DNA Replication/drug effects , Disulfides/analysis , Humans , Insulin-Like Growth Factor II/metabolism , Insulin-Like Growth Factor II/pharmacology , Insulin-Like Growth Factor II/physiology , Isoelectric Focusing , Molecular Weight , Neuroblastoma , Thymidine/metabolismABSTRACT
Rhabdomyosarcoma is the most common soft tissue sarcoma of childhood and appears to arise from developing striated muscle-forming cells. Since insulin-like growth factor II (IGF-II) is involved in normal muscle growth and maturation and elevated IGF-II mRNA levels have previously been reported in rhabdomyosarcomas, we have been studying the possible role of IGF-II in the unregulated growth and invasive potential of these embryonal tumors. In this study, we demonstrate that 13 of 14 rhabdomyosarcoma tumors express high levels of IGF-II mRNA relative to normal adult muscle and also express mRNA for the type I IGF receptors on their cell surface, the receptor thought to mediate the effects of IGF-II on muscle cells. We have established several rhabdomyosarcoma cell lines in mitogen-free media and demonstrate that these cells express type I IGF receptors on their cell surface and secrete IGF-II into the media. Exogenous IGF-II is able to stimulate cellular motility in these cell lines as assayed in a modified Boyden chamber. Finally, alpha IR-3, a type I receptor antagonist, inhibits the growth of these cell lines in serum-free media but does not inhibit IGF-II-induced motility of these cells. These data suggest that endogenously produced IGF-II functions as an autocrine growth and motility factor in many rhabdomyosarcoma tumors. The mitogenic actions of IGF-II are mediated through a domain of the type I IGF receptor that is blocked by alpha IR-3. IGF-II-induced motility may be mediated through an alternative signaling pathway.
Subject(s)
Insulin-Like Growth Factor II/physiology , Neoplasm Proteins/physiology , Rhabdomyosarcoma/pathology , Soft Tissue Neoplasms/pathology , Cell Division/drug effects , Cell Movement/drug effects , Humans , Insulin-Like Growth Factor II/pharmacology , Muscles/chemistry , RNA, Messenger/analysis , RNA, Neoplasm/analysis , Receptor, IGF Type 2 , Receptors, Cell Surface/immunology , Receptors, Cell Surface/metabolism , Receptors, Somatomedin , Rhabdomyosarcoma/chemistry , Soft Tissue Neoplasms/chemistryABSTRACT
Insulin-like growth factor II (IGF-II) mRNA was increased in two of eight neuroblastomas and in eight of eight pheochromocytomas, tumors of the adrenal medulla that occur in childhood and adulthood, respectively. RNA encoding the type I IGF receptor, the receptor thought to mediate the mitogenic effects of IGF-I and IGF-II, also was uniformly expressed in these cells. To assess the role of IGF-II in the growth of these tumor cells, we have used the SK-N-AS cultured neuroblastoma cell line, which can be continuously propagated in mitogen-free medium, as a model system. Our results strongly suggest that IGF-II, synthesized by SK-N-AS cells and acting through type I IGF receptors, contributes to the autonomous growth of this tumor cell line. (a) SK-N-AS cells synthesized large amounts of IGF-II RNA and secreted greater than 50 ng/ml of IGF-II (as determined by specific radioimmuno- and radioreceptor assays). Little, if any, IGF-I RNA or immunoreactive IGF-I were detected. (b) SK-N-AS cells possess type I IGF receptors. (c) Exogenous IGF-I and IGF-II stimulated DNA synthesis in SK-N-AS cells, and this stimulation was abolished by a blocking antibody to the type I IGF receptor. (d) This anti-receptor antibody also abolished the multiplication of SK-N-AS cells in the absence of added mitogens. We conclude that IGF-II is an autocrine growth factor for SK-N-AS cells and suggest that this mechanism may contribute to the growth of some adrenal medullary tumors.
